Search Results - "L Karlin"

Home range size, vegetation density, and season influences prey use by coyotes (Canis latrans) by Ward, Jennifer N, Hinton, Joseph W, Johannsen, Kristina L, Karlin, Melissa L, Miller, Karl V, Chamberlain, Michael J

“…To ensure reproductive success, Canis species establish contiguous mosaics of territories in suitable habitats to partition space and defend limiting…”
Get full text

Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study by Leclerc, V., Karlin, L., Herledan, C., Marchal, L., Baudouin, A., Gouraud, A., Caffin, A. G., Larbre, V., Lazareth, A., Bachy, E., Salles, G., Ghesquières, H., Rioufol, C., Ranchon, F.

“…Purpose The aim of this study is to assess international guidelines implementation concerning thromboprophylaxis strategy in myeloma patients treated with…”
Get full text

French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry by Ferment, B., Lambert, J., Caillot, D., Lafon, I., Karlin, L., Lazareth, A., Touzeau, C., Leleu, X., Moya, N., Harel, S., Perrot, A., Bories, P., Vincent, L., Lamure, S., Mohty, M., Malard, F., Manier, S., Yakoub‐Agha, I., Schiano De Colella, J.‐M., Brisou, G., Talbot, A., Decaux, O., Houot, R., Le Gouill, S., Bigot, N., Facon, T., Corre, J., Moreau, P., Arnulf, B.

“…Summary Idecabtagene vicleucel (ide‐cel), a chimeric antigen receptor T‐cell therapy targeting B‐cell maturation antigen (BCMA), received early access program…”
Get full text

Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression by Mowery, Cody T., Reyes, Jaime M., Cabal-Hierro, Lucia, Higby, Kelly J., Karlin, Kristen L., Wang, Jarey H., Kimmerling, Robert J., Cejas, Paloma, Lim, Klothilda, Li, Hubo, Furusawa, Takashi, Long, Henry W., Pellman, David, Chapuy, Bjoern, Bustin, Michael, Manalis, Scott R., Westbrook, Thomas F., Lin, Charles Y., Lane, Andrew A.

“…Down syndrome (DS, trisomy 21) is associated with developmental abnormalities and increased leukemia risk. To reconcile chromatin alterations with…”
Get full text

Mutations in the transcriptional repressor REST predispose to Wilms tumor by Mahamdallie, Shazia S, Hanks, Sandra, Karlin, Kristen L, Zachariou, Anna, R Perdeaux, Elizabeth, Ruark, Elise, Shaw, Chad A, Renwick, Alexander, Ramsay, Emma, Yost, Shawn, Elliott, Anna, Birch, Jillian, Capra, Michael, Gray, Juliet, Hale, Juliet, Kingston, Judith, Levitt, Gill, McLean, Thomas, Sheridan, Eamonn, Renwick, Anthony, Seal, Sheila, Stiller, Charles, Sebire, Neil, Westbrook, Thomas F, Rahman, Nazneen

“…Nazneen Rahman and colleagues identify inactivating germline mutations in the gene encoding the transcriptional repressor REST in familial and non-familial…”
Get full text

Tcf3 promotes cell migration and wound repair through regulation of lipocalin 2 by Miao, Qi, Ku, Amy T., Nishino, Yudai, Howard, Jeffrey M., Rao, Ajay S., Shaver, Timothy M., Garcia, Gloria E., Le, Diep N., Karlin, Kristen L., Westbrook, Thomas F., Poli, Valeria, Nguyen, Hoang

“…Cell migration is an integral part of re-epithelialization during skin wound healing, a complex process involving molecular controls that are still largely…”
Get full text

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study by Macro, M., Hulin, C., Vincent, L., Charvet-Rumpler, A., Benboubker, L., Calmettes, C., Stoppa, A.-M., Laribi, K., Clement-Filliatre, L., Zerazhi, H., Honeyman, F., Richez, V., Maloisel, F., Karlin, L., Barrak, J., Chouaid, C., Leleu, X.

“…Ixazomib (IXA) is an oral proteasome inhibitor (PI) used in combination with lenalidomide and dexamethasone (IXA-Rd) for patients with relapsed and/or…”
Get full text

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients by Hebraud, B, Leleu, X, Lauwers-Cances, V, Roussel, M, Caillot, D, Marit, G, Karlin, L, Hulin, C, Gentil, C, Guilhot, F, Garderet, L, Lamy, T, Brechignac, S, Pegourie, B, Jaubert, J, Dib, M, Stoppa, A-M, Sebban, C, Fohrer, C, Fontan, J, Fruchart, C, Macro, M, Orsini-Piocelle, F, Lepeu, G, Sohn, C, Corre, J, Facon, T, Moreau, P, Attal, M, Avet-Loiseau, H

“…Deletions of the 1p region appear as a pejorative prognostic factor in multiple myeloma patients (especially 1p22 and 1p32 deletions) but there is a lack of…”
Get full text

Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort by Chalopin, T., Macro, M., Decaux, O., Royer, B., Gounot, R., Bobin, A., Karlin, L., Mohty, M., Frenzel, L., Perrot, A., Manier, S., Vincent, L., Dib, M., Slama, B., Richez, V., Allangba, O., Zunic, P., Newinger-Porte, M., Mariette, C., Joly, B., Gay, J., Botoc, I., Malfuson, JV, Garlantezec, R., Hulin, C.

“…Multiple myeloma patients aged 80 years and older are a population more prone to comorbidities and frailty. We aim to describe the real-life management and…”
Get full text

Geographic patterns in morphometric and genetic variation for coyote populations with emphasis on southeastern coyotes by Hinton, Joseph W., Heppenheimer, Elizabeth, West, Kyla M., Caudill, Danny, Karlin, Melissa L., Kilgo, John C., Mayer, John Joseph, Miller, Karl V., Walch, Margaret, vonHoldt, Bridgett, Chamberlain, Michael J.

“…Prior to 1900, coyotes (Canis latrans) were restricted to the western and central regions of North America, but by the early 2000s, coyotes became ubiquitous…”
Get full text

Long-term use of liposomal nebulized amikacin and tedizolid for the treatment of disseminated nocardiosis after allogeneic hematopoietic stem cell transplantation by Soueges, Sarah, Triffault-Fillit, Claire, Roux, Sandrine, Labussière-Wallet, Hélène, Lebeaux, David, Dumitrescu, Oana, Morelec, Isabelle, Hodille, Elisabeth, Ader, Florence

“…Nocardiosis is a life-threatening opportunistic infection in immunocompromised patients. Herein, we present successful adjunctive use of liposomal nebulized…”
Get full text

The Oncogenic STP Axis Promotes Triple-Negative Breast Cancer via Degradation of the REST Tumor Suppressor by Karlin, Kristen L., Mondal, Gourish, Hartman, Jessica K., Tyagi, Siddhartha, Kurley, Sarah J., Bland, Chris S., Hsu, Tiffany Y.T., Renwick, Alexander, Fang, Justin E., Migliaccio, Ilenia, Callaway, Celetta, Nair, Amritha, Dominguez-Vidana, Rocio, Nguyen, Don X., Osborne, C. Kent, Schiff, Rachel, Yu-Lee, Li-Yuan, Jung, Sung Y., Edwards, Dean P., Hilsenbeck, Susan G., Rosen, Jeffrey M., Zhang, Xiang H.-F., Shaw, Chad A., Couch, Fergus J., Westbrook, Thomas F.

“…Defining the molecular networks that drive breast cancer has led to therapeutic interventions and improved patient survival. However, the aggressive…”
Get full text

ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma by Arabzade, Amir, Zhao, Yanhua, Varadharajan, Srinidhi, Chen, Hsiao-Chi, Jessa, Selin, Rivas, Bryan, Stuckert, Austin J, Solis, Minerva, Kardian, Alisha, Tlais, Dana, Golbourn, Brian J, Stanton, Ann-Catherine J, Chan, Yuen San, Olson, Calla, Karlin, Kristen L, Kong, Kathleen, Kupp, Robert, Hu, Baoli, Injac, Sarah G, Ngo, Madeline, Wang, Peter R, De León, Luz A, Sahm, Felix, Kawauchi, Daisuke, Pfister, Stefan M, Lin, Charles Y, Hodges, H Courtney, Singh, Irtisha, Westbrook, Thomas F, Chintagumpala, Murali M, Blaney, Susan M, Parsons, Donald W, Pajtler, Kristian W, Agnihotri, Sameer, Gilbertson, Richard J, Yi, Joanna, Jabado, Nada, Kleinman, Claudia L, Bertrand, Kelsey C, Deneen, Benjamin, Mack, Stephen C

“…More than 60% of supratentorial ependymomas harbor a (ZR ) gene fusion (formerly ). To study the biology of ZR , we developed an autochthonous mouse tumor…”
Get more information

1567 Overview of French routine clinical practice for the management of chemotherapy-induced anemia (CIA) with biosimilar epoetin alfa in 1298 patients with solid tumors: A national observational study (The OncoBOS study) by Metges, J.P, Khobta, N, Boschetti, G, Karlin, L, Toledano, A, Aubron-olivier, C, Fernet, D, Fitoussi, O

Get full text

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES by A Nooka, A Lesokhin, M Mohty, R Niesvizky, C Maisel, B Arnulf, S Larson, A Varshavsky-Yanovsky, X Leleu, L Karlin, D Vesole, N Bahlis, CF Larrea, N Raje, E Leip, U Conte, M Elmeliegy, A Viqueira, V Blunk, S Manier

“…Introduction/Objectives: To evaluate the efficacy and safety of elranatamab in a pooled analysis of patients (pts) enrolled in MagnetisMM trials with relapsed…”
Get full text

Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study by Sens, Florence, Chaintreuil, Déborah, Jolivot, Anne, Guebre-Egziabher, Fitsum, Robinson, Philip, Karlin, Lionel, Bridoux, Frank, Juillard, Laurent

“…In patients with cast nephropathy and acute kidney injury (AKI) requiring dialysis, the reduction of serum free light chains (FLC) using chemotherapy and…”
Get more information

P1739: HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE 1B/2A OPEN‐LABEL DOSE ESCALATION STUDY by Donk, N. W., Guo, S., Shi, L., Lord‐Bessen, J., Tang, D., Karlin, L., Weisel, K., Ramasamy, K., Abad, P. C., Amin, A., Amin, S., Lonial, S.

Get full text

S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH‐RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018‐04 by Touzeau, C., Perrrot, A., Hulin, C., Manier, S., Macro, M., Chretien, M.‐L., Karlin, L., Decaux, O., Jacquet, C., Tiab, M., Leleu, X., Planchce, L., Avet‐Loiseau, H., Moreau, P.

Get full text

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma by Fouquet, G., Pegourie, B., Macro, M., Petillon, M.O., Karlin, L., Caillot, D., Roussel, M., Arnulf, B., Mathiot, C., Marit, G., Kolb, B., Stoppa, A.M., Brechiniac, S., Richez, V., Rodon, P., Banos, A., Wetterwald, M., Garderet, L., Royer, B., Hulin, C., Benbouker, L., Decaux, O., Escoffre-Barbe, M., Fermand, J.P., Attal, M., Avet-Loiseau, H., Moreau, P., Facon, T., Leleu, X.

“…The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM)…”
Get full text

B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORK by Roussel, M., Pirotte, M., Gounot, R., Queru, K., Rizzo, O., Royer, B., Harel, S., Desport, E., Huart, A., Niault, M., Karlin, L., Decaux, O., Chalopin, T., Carpentier, B., Macro, M., Vignon, M., Chalayer, E., Stoppa, AM, Bridoux, F., Jaccard, A.

Get full text